Results 111 to 120 of about 264,642 (338)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell & Bioscience, 2018
Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain tumors and host immune cells, and its expression can be induced or maintained
Fei Tang, Pan Zheng
doaj   +1 more source

PD-L1 is not constitutively expressed on tasmanian devil facial tumor cells but is strongly upregulated in response to IFN-gamma and can be expressed in the tumor microenvironment [PDF]

, 2016
The devil facial tumor disease (DFTD) is caused by clonal transmissible cancers that have led to a catastrophic decline in the wild Tasmanian devil (Sarcophilus harrisii) population.
Corcoran, L., Flies, A., Hayball, J., Knowles, G., Lyons, A., Murphy, J., Papenfuss, A., Woods, G.   +7 more
core   +2 more sources

Membrane Fusion‐Inspired Nanomaterials: Emerging Strategies for Infectious Disease and Cancer Diagnostics

Advanced Healthcare Materials, EarlyView.
Membrane fusion‐inspired nanomaterials offer transformative potential in diagnostics by mimicking natural fusion processes to achieve highly sensitive and specific detection of disease biomarkers. This review highlights recent advancements in nanomaterial functionalization strategies, signal amplification systems, and stimuli‐responsive fusion designs,
Sojeong Lee, Khulan Nyamzaya, Jueun Han, Yejin Song, Jihee Lee, Jung Hyun Jo, Seungmin Bang, Eun‐Kyung Lim, Seungjoo Haam, Eunjung Kim   +9 more
wiley   +1 more source

GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer

Heliyon
The programmed death-ligand 1 (PD-L1) on the surface of tumor cells binds to the receptor programmed cell death protein 1 (PD-1) on effector T cells, thereby inhibiting the anti-tumor immune response. Immune checkpoint blockade (ICB) therapy targeting PD-
Xue Sun, Mingen Lin, Ziyin Tian, Yan Ma, Lei Lv   +4 more
doaj   +1 more source

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]

, 2018
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim, Crosetti, Anna M, Cummings, Amy L, Drakaki, Alexandra, Faiena, Izak, Pantuck, Allan J   +5 more
core   +1 more source

Integrin β4‐Enriched Small Extracellular Vesicle as Drug Delivery Vehicle for Targeting Pulmonary Metastasis of Hepatocellular Carcinoma

Advanced Healthcare Materials, EarlyView.
The expression of integrin β4 (ITGβ4) on small extracellular vesicle (sEV) correlates with lung‐tropism. Enrichment of ITGβ4 on sEVs enhances their lung‐targeting ability. The sEVs loaded with doxorubicin exhibit superior therapeutic efficacy in a lung metastasis mouse model.
Tung Him Ng, Aijun Liang, Maximus CF Yeung, Sze Keong Tey, Kam‐Leung Siu, Sin‐Yee Fung, Dong‐Yan Jin, Judy Wai Ping Yam   +7 more
wiley   +1 more source

Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction

Cell Reports
Summary: The CTLA-4 and PD-1 checkpoints control immune responses and are key targets in immunotherapy. Both pathways are connected via a cis interaction between CD80 and PD-L1, the ligands for CTLA-4 and PD-1, respectively. This cis interaction prevents
Maximillian A. Robinson, Alan Kennedy, Carolina T. Orozco, Hung-Chang Chen, Erin Waters, Dalisay Giovacchini, Kay Yeung, Lily Filer, Claudia Hinze, Christopher Lloyd, Simon J. Dovedi, David M. Sansom   +11 more
doaj   +1 more source

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells [PDF]

, 2014
Programmed death ligand 1 (PD-L1) is an immunosuppressive molecule expressed by many cancer types, including a large proportion of head and neck cancers (HNC), and ligation of its receptor, programmed death 1 (PD-1), induces exhaustion of effector T ...
Concha-Benavente, Fernando, Ferris, Robert L   +1 more
core   +2 more sources

Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology

Advanced Healthcare Materials, EarlyView.
In vitro breast cancer models that closely mimic the complex biological and cellular interactions within the tumor microenvironment hold strong promise for enhancing our understanding of tumor progression, immune system behavior, and resistance to therapies, which are essential for developing personalized cancer treatments. Abstract Engineered in vitro
Wonwoo Jeong, Sang Jin Lee
wiley   +1 more source

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma [PDF]

, 2017
Background Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in several cancer types. Methods We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-
Berghoff, Anna Sophie, Brandstetter, Anita, Dieckmann, Karin, Filipits, Martin, Hainfellner, Johannes A., Hegi, Monika E., Kiesel, Barbara, Kurscheid, Sebastian, Marosi, Christine, Preusser, Matthias, Rajky, Orsolya, Ricken, Gerda, Weller, Michael, Wick, Wolfgang, Widhalm, Georg, Wöhrer, Adelheid, Zielinski, Christoph C.   +16 more
core